NYSE:UNH

UnitedHealth Group Inc (UNH)

424.72
-3.47 (0.81%)
as of Jul 8, 2026, 10:00:07 pm Market Open.
288 watching
0
Investor Insights
star iconJul 8, 2026, 12:00 am

This summary was created by AI, based on 41 opinions in the last 12 months.

UnitedHealth Group Inc (UNH) faces a complex set of challenges and opportunities as experts express mixed sentiments about its future. On one hand, there is optimism regarding its recovery potential, driven by leadership changes, historical success, and potential growth in earnings as medical costs stabilize. However, many analysts are concerned about sustained pressures from regulatory scrutiny, rising healthcare costs, and shifts in Medicare policies. While some see it as a defensive play with the potential for significant upside, others caution against investing due to a reputation for volatility and uncertain future prospects. Analysts point to a strong reliance on US federal funding and highlight the impact of broader economic factors affecting the healthcare sector overall.

consensus icon
Consensus
Mixed
valuation icon
Valuation
Undervalued
review icon
Similar
CVS
PAST TOP PICK

(A Top Pick May 20/16. Up 46.72%.) He’s been really happy with this. This is definitely the leader in their group. Management is intent on returning capital, 50% of earnings and cash flow each year.

PAST TOP PICK

(A Top Pick May 20/16. Up 40%.) The whole healthcare space is at a neutral. This is the biggest Medicare/Medicaid provider in the US. They are great operators and have got scale. Great management team.

TOP PICK

He likes its scale. It is the leader in every single group that it does business in. It has the widest geographic dispersion for its businesses. It is driving costs down for the government spend, which they badly need. Dividend yield of 1.6%. (Analysts’ price target is $194.)

TOP PICK

The largest health insurer in the US. There are strong structural tailwinds within the managed care subsector and some potential tax windfalls. They’ve been using their health scripts to win business and reduce costs. Dividend yield of 1.4%. (Analysts’ price target is $191.)

PAST TOP PICK

(Top Pick Mar 2/17, Up 39%) There is a move toward trying to reduce the per capita health care spending. They are compressing their business and picking up a lot of CVS-N customers. It is not terribly affected either way by a policy shift. They return 50% of free cash flow to shareholders. They have government contracts behind them. It came off his list, but there is nothing wrong with them.

DON'T BUY

He is not adding to his holdings right now. The industry leader in terms of health insurance. The time when he really backed up the truck was in the early part of Mr. Obama’s administration when stocks were just begging to be picked up off the sidewalks. Since then, this company has done extremely well. For your healthcare exposure, he would be looking at the more traditional companies such as Abbott Labs, Pfizer’s, Merck’s, GlaxoSmithKline’s.

PAST TOP PICK

(A Top Pick June 22/16. Up 17.44%.) They are the dominant medical insurer. The transition from straight Medicare to Medicare Advantage will be a positive tailwind for them. There are some tax benefits coming down the pipeline that will be positive for them. The only US medical insurer that is integrated with its pharmacy benefit manager, which is proving to be positive.

HOLD

A very high quality health care provider in the US. If you want exposure there, it is one of the best companies to hold. She likes healthcare as a secular theme due to the aging demographics. There is not one specific reason why is has gone up recently. Keep holding it.

COMMENT

Technically this has been doing okay, but it is currently testing its support level, and trading in a range right now. Historically, healthcare stocks at this time of year have underperformed the market. It is best not to be in the stock right now.

COMMENT

A great business, and a leader in Pharma/benefits management space. Their franchise of Optum has been eating up market share in that fragmented space. Also, have contracts with the US military. Thinks it could have a little bit of volatility if there is a Clinton president, which could give you a buying opportunity.

WAIT

It is coming in under EBV+5, or $116.81, -14% to model price. We are getting 9% compound health care cost increases in the US annually. Wait for $110, EBV+4, to buy the stock again.

PAST TOP PICK

(A Top Pick Aug 27/15. Up 18.02%.) Recently took profits on this. The healthcare sector is under little pressure with some of the rhetoric coming out of the election talk in the US. He still likes this, but it might hold back a little by more talk from the US politics.

PAST TOP PICK

(A Top Pick July 9/15. Up 19.48%.) He owns a number of themes in the US that are not driven by the economy. Spending in health care is rising in the US.

TOP PICK

HMOs have really benefited from the Affordable Care Act with new lives coming on to getting insurance. Also, benefiting from lower employment rates. This is the “elephant in the room” in healthcare insurance in the US. Dividend yield of 1.81%.

PAST TOP PICK

(A Top Pick July 9/15. Up 17%.) The largest provider of healthcare coverage. The US has about 50 million subscribers, about 4 million in Brazil. They are in 125 countries globally. This is still a Buy.

Showing 226 to 240 of 287 entries